Analyst firms · UBS · GSK
UBS GSK price target and rating history
GSK plc (GSK) · Health Care
UBS rates GSK plc (GSK) Neutral, as of its latest action on Jul 8, 2024. It has published 3 rating actions on GSK since November 2022, including 0 upgrades and 2 downgrades.
- Current rating
- Neutral
- Price target
- Not stated
- Median target, all firms
- Too few
- Actions on GSK
- 3
Every UBS rating on GSK
- Jul 8, 2024DowngradeUBS downgrades to Neutral from Buy
- Jan 16, 2024
- Nov 11, 2022DowngradeUBS downgrades to Sell from Neutral
How other firms rate GSK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Hold | $55.90 | Oct 29, 2026 |
| Wolfe Research | Outperform | $70 | Oct 9, 2026 |
| Berenberg | Buy | Sep 15, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Citigroup | Neutral | Jul 24, 2026 | |
| HSBC | Hold | Jul 6, 2026 | |
| Barclays | Underweight | Jan 6, 2026 | |
| BofA Securities | Neutral | Nov 25, 2025 |
Questions about UBS and GSK
- What is UBS's rating on GSK?
- UBS rates GSK Neutral, a neutral rating, as of Jul 8, 2024.
- When did UBS last change its view on GSK?
- On Jul 8, 2024, UBS downgrades to Neutral from Buy.
More GSK rating histories
All UBS ratingsGSK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.